• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Increased plasma osteoprotegerin concentrations are associated with indices of bone strength of the hip.血浆骨保护素浓度升高与髋部骨强度指标相关。
J Clin Endocrinol Metab. 2008 May;93(5):1789-95. doi: 10.1210/jc.2007-2492. Epub 2008 Feb 26.
2
The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study.老年人血清骨保护素与核因子κB受体活化因子配体的性别特异性关联及其与骨密度的关系:兰乔贝纳多研究
Eur J Endocrinol. 2007 May;156(5):555-62. doi: 10.1530/EJE-06-0753.
3
Association of genetic polymorphisms of RANK, RANKL and OPG with bone mineral density in Chinese peri- and postmenopausal women.中国绝经前后妇女 RANK、RANKL 和 OPG 基因多态性与骨密度的关系。
Clin Biochem. 2013 Oct;46(15):1493-501. doi: 10.1016/j.clinbiochem.2013.03.011. Epub 2013 Mar 24.
4
Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.绝经后女性血清核因子-κB 受体活化因子配体、骨保护素、高敏 C 反应蛋白与骨密度之间的关系:骨免疫与骨炎症
Menopause. 2009 Sep-Oct;16(5):950-5. doi: 10.1097/gme.0b013e3181a181b8.
5
Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study.与骨保护素和核因子-κB 配体相关的骨丢失:特罗姆瑟研究。
Osteoporos Int. 2010 Jun;21(6):931-8. doi: 10.1007/s00198-009-1035-6. Epub 2009 Aug 22.
6
Gene-gene interactions in RANK/RANKL/OPG system influence bone mineral density in postmenopausal women.RANK/RANKL/OPG 系统中的基因-基因相互作用影响绝经后妇女的骨密度。
J Steroid Biochem Mol Biol. 2010 Jan;118(1-2):102-6. doi: 10.1016/j.jsbmb.2009.10.013. Epub 2009 Nov 5.
7
Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis.肾结石患者低骨量与血清核因子κB受体活化因子配体(RANKL)及骨保护素(OPG)之间的关联
BMC Nephrol. 2018 Jul 11;19(1):172. doi: 10.1186/s12882-018-0960-z.
8
Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.在双膦酸盐治疗的骨质疏松症患者中,核因子κB受体活化因子配体/骨保护素系统的变化与骨密度的变化相关。
Osteoporos Int. 2006;17(5):693-703. doi: 10.1007/s00198-005-0035-4. Epub 2006 Jan 25.
9
In peripubertal girls, artistic gymnastics improves areal bone mineral density and femoral bone geometry without affecting serum OPG/RANKL levels.在青春期前的女孩中,艺术体操可改善骨面积密度和股骨骨几何形状,而不影响血清 OPG/RANKL 水平。
Osteoporos Int. 2011 Dec;22(12):3055-66. doi: 10.1007/s00198-011-1541-1. Epub 2011 Feb 26.
10
Polymorphisms in genes in the RANKL/RANK/OPG pathway are associated with bone mineral density at different skeletal sites in post-menopausal women.RANKL/RANK/OPG通路中的基因多态性与绝经后女性不同骨骼部位的骨密度相关。
Osteoporos Int. 2015 Jan;26(1):179-85. doi: 10.1007/s00198-014-2854-7. Epub 2014 Aug 20.

引用本文的文献

1
Adipose-Derived Stromal Cell Conditioned Medium on Bone Remodeling: Insights from a 3D Osteoblast-Osteoclast Co-Culture Model.脂肪来源基质细胞条件培养基对骨重塑的影响:来自三维成骨细胞-破骨细胞共培养模型的见解
Calcif Tissue Int. 2025 Jan 7;116(1):26. doi: 10.1007/s00223-024-01335-9.
2
Delineating the relationship between circulating osteoprotegerin and bone health in women with a pathogenic variant in : A cross-sectional analysis.明确携带致病变体的女性循环骨保护素与骨骼健康之间的关系:一项横断面分析。
Bone Rep. 2024 Sep 6;22:101802. doi: 10.1016/j.bonr.2024.101802. eCollection 2024 Sep.
3
Clinical Data for Parametrization of Bone Models Incorporating Cell-Cytokine Dynamics: A Systematic Review of Literature.纳入细胞-细胞因子动力学的骨模型参数化临床数据:文献系统评价
Front Bioeng Biotechnol. 2022 Jul 12;10:901720. doi: 10.3389/fbioe.2022.901720. eCollection 2022.
4
Delineating the role of osteoprotegerin as a marker of breast cancer risk among women with a BRCA1 mutation.确定骨保护素在携带BRCA1突变的女性乳腺癌风险标志物中的作用。
Hered Cancer Clin Pract. 2022 Apr 13;20(1):14. doi: 10.1186/s13053-022-00223-3.
5
RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling.RANKL/RANK/OPG 通路:运动诱导骨重塑的机制。
Biomed Res Int. 2020 Feb 19;2020:6910312. doi: 10.1155/2020/6910312. eCollection 2020.
6
Comprehensive assessment of tissue and serum parameters of bone metabolism in a series of orthopaedic patients.对一系列骨科患者的组织和血清骨代谢参数进行综合评估。
PLoS One. 2019 Dec 27;14(12):e0227133. doi: 10.1371/journal.pone.0227133. eCollection 2019.
7
Antagonistic Pleiotropy in Human Disease.人类疾病中的拮抗多效性
J Mol Evol. 2020 Jan;88(1):12-25. doi: 10.1007/s00239-019-09923-2. Epub 2019 Dec 21.
8
Circulating levels of dickkopf-1, osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults.循环中的 Dickkopf-1、骨保护素和硬化蛋白水平在老年人中高于年轻人,并且与老年人的全身骨矿物质密度呈正相关。
Osteoporos Int. 2017 Sep;28(9):2683-2689. doi: 10.1007/s00198-017-4104-2. Epub 2017 Jun 5.
9
Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort.骨保护素与激素受体亚型相关的乳腺癌风险:欧洲癌症与营养前瞻性调查(EPIC)队列中的一项巢式病例对照研究
BMC Med. 2017 Feb 8;15(1):26. doi: 10.1186/s12916-017-0786-8.
10
Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a cross-sectional, observational study.胱抑素C作为健康男性骨保护素水平的潜在预测指标:一项横断面观察性研究。
BMC Musculoskelet Disord. 2015 Aug 28;16:227. doi: 10.1186/s12891-015-0684-1.

本文引用的文献

1
The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study.老年人血清骨保护素与核因子κB受体活化因子配体的性别特异性关联及其与骨密度的关系:兰乔贝纳多研究
Eur J Endocrinol. 2007 May;156(5):555-62. doi: 10.1530/EJE-06-0753.
2
The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys.RANKL抑制剂OPG-Fc可增加年轻性腺完整的食蟹猴的皮质骨和小梁骨量。
Osteoporos Int. 2007 Aug;18(8):1073-82. doi: 10.1007/s00198-007-0363-7. Epub 2007 Mar 24.
3
Proximal hip geometry is linked to several chromosomal regions: genome-wide linkage results from the Framingham Osteoporosis Study.近端髋部几何结构与多个染色体区域相关联:弗雷明汉骨质疏松症研究的全基因组连锁分析结果。
Bone. 2007 Mar;40(3):743-50. doi: 10.1016/j.bone.2006.09.020. Epub 2006 Oct 31.
4
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures.对全球骨质疏松性骨折的患病率及相关残疾情况的一项评估。
Osteoporos Int. 2006 Dec;17(12):1726-33. doi: 10.1007/s00198-006-0172-4. Epub 2006 Sep 16.
5
Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment.循环骨保护素与核因子κB受体活化因子配体:在代谢性骨病评估中的临床应用
J Clin Endocrinol Metab. 2005 Nov;90(11):6323-31. doi: 10.1210/jc.2005-0794. Epub 2005 Aug 16.
6
In vivo short-term precision of hip structure analysis variables in comparison with bone mineral density using paired dual-energy X-ray absorptiometry scans from multi-center clinical trials.在多中心临床试验中,使用配对双能X线吸收法扫描,比较髋部结构分析变量与骨密度的体内短期精度。
Bone. 2005 Jul;37(1):112-21. doi: 10.1016/j.bone.2005.03.007.
7
Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover.血清骨保护素及其与骨密度和骨转换标志物的关系。
Osteoporos Int. 2005 Apr;16(4):417-23. doi: 10.1007/s00198-004-1699-x. Epub 2004 Jul 20.
8
The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.绝经后女性激素治疗后循环骨保护素的变化及其与骨骼雌激素反应性的关系。
Clin Endocrinol (Oxf). 2005 Mar;62(3):349-53. doi: 10.1111/j.1365-2265.2005.02221.x.
9
The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women.血清骨保护素对绝经后女性骨量和椎体骨折的影响
Osteoporos Int. 2005 Nov;16(11):1368-74. doi: 10.1007/s00198-005-1844-1. Epub 2005 Feb 12.
10
Osteoclastogenesis inhibitory factor/osteoprotegerin reduced bone loss induced by mechanical unloading.破骨细胞生成抑制因子/骨保护素减少了机械卸载诱导的骨质流失。
Calcif Tissue Int. 2004 Oct;75(4):338-43. doi: 10.1007/s00223-004-0028-x. Epub 2004 Jul 30.

血浆骨保护素浓度升高与髋部骨强度指标相关。

Increased plasma osteoprotegerin concentrations are associated with indices of bone strength of the hip.

作者信息

Samelson Elizabeth J, Broe Kerry E, Demissie Serkalem, Beck Thomas J, Karasik David, Kathiresan Sekar, Kiel Douglas P

机构信息

Institute for Aging Research, Hebrew SeniorLife, 1200 Centre Street, Boston, MA 02131, USA.

出版信息

J Clin Endocrinol Metab. 2008 May;93(5):1789-95. doi: 10.1210/jc.2007-2492. Epub 2008 Feb 26.

DOI:10.1210/jc.2007-2492
PMID:18303076
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2386280/
Abstract

OBJECTIVE

Osteoprotegerin (OPG) is an important regulator of bone turnover through its effects on osteoclastogenesis, yet findings from previous studies of circulating OPG and commonly measured bone indices in humans have been conflicting. We conducted a cross-sectional study to evaluate the association between plasma OPG and femoral neck (FN) bone density (BMD) and geometry in a large cohort of women and men.

DESIGN

Participants included 1379 postmenopausal women and 1165 men, aged 50-89 yr (mean, 64 yr), in the Framingham Offspring Study. Dual x-ray absorptiometry was used to evaluate FN BMD and geometry (bone width, section modulus, and cross-sectional area at the narrow neck region). Plasma OPG concentrations were measured by ELISA. Sex-specific analysis of covariance was used to calculate means and assess linear trend in BMD and geometry values across OPG quartiles, adjusted for confounders.

RESULTS

OPG concentrations were greater in women than men, increased with age, and were greater in smokers and those with diabetes and heart disease. Multivariable-adjusted mean FN BMD in women increased from the lowest to the highest OPG quartile (trend, P < 0.01). However, no linear trend between FN BMD and OPG was observed in men (trend, P = 0.34). Section modulus and bone width increased with OPG in men (trend, P < 0.01), whereas no association between hip geometry indices and OPG was observed in women.

CONCLUSION

Higher OPG concentration may indicate greater skeletal strength in women and men, possibly through reducing bone loss in women and increasing periosteal apposition in men.

摘要

目的

骨保护素(OPG)通过对破骨细胞生成的影响,是骨转换的重要调节因子,但先前关于人体循环OPG与常用骨指标的研究结果相互矛盾。我们进行了一项横断面研究,以评估一大群男性和女性中血浆OPG与股骨颈(FN)骨密度(BMD)及几何形态之间的关联。

设计

参与者包括弗雷明汉后代研究中1379名50 - 89岁(平均64岁)的绝经后女性和1165名男性。采用双能X线吸收法评估FN的BMD和几何形态(骨宽度、截面模量以及狭窄颈部区域的横截面积)。通过酶联免疫吸附测定法测量血浆OPG浓度。采用性别特异性协方差分析来计算均值,并评估经混杂因素校正后,OPG四分位数组中BMD和几何形态值的线性趋势。

结果

女性的OPG浓度高于男性,随年龄增加而升高,在吸烟者以及患有糖尿病和心脏病的人群中更高。多变量校正后,女性中从最低到最高OPG四分位数组,平均FN BMD升高(趋势,P < 0.01)。然而,在男性中未观察到FN BMD与OPG之间的线性趋势(趋势,P = 0.34)。男性的截面模量和骨宽度随OPG升高(趋势,P < 0.01),而在女性中未观察到髋部几何形态指标与OPG之间的关联。

结论

较高的OPG浓度可能表明男性和女性的骨骼强度更大,可能是通过减少女性的骨质流失以及增加男性的骨膜附着来实现的。